A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : IVIVE / in vitro-in vivo extrapolation

[Related PubMed/MEDLINE]
Total Number of Papers: 169
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   IVIVE  (>> Co-occurring Abbreviation)
Long Form:   in vitro-in vivo extrapolation
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2023 Quantitative Interpretation of ToxTracker Dose Response Data for Potency Comparisons and Mode-of-Action Determination. AED, BMD, PCA
2023 [In vitro in vivo extrapolation (IVIVE) in safety pharmacology to improve human predictability -new evaluation systems for new drug modalities]. ---
2022 A weight of evidence approach for bioaccumulation assessment. BAFs, BAT, BCF, beta-HCH, BMF, DETs, HCB, LOE, QSARs, SETAC, TMFs, WoE
2022 Analysis of Time-Dependent Pharmacokinetics Using In Vitro-In Vivo Extrapolation and Physiologically Based Pharmacokinetic Modeling. PBPK, TDPK
2022 Cabozantinib Carries the Risk of Drug-Drug Interactions via Inhibition of UDPglucuronosyltransferase (UGT) 1A9. DDIs, TKI, UGT
2022 Comprehensive interpretation of in vitro micronucleus test results for 292 chemicals: from hazard identification to risk assessment application. AEDs, BER, BMC, PODs
2022 DallphinAtoM: Physiologically based pharmacokinetics software predicting human PK parameters based on physicochemical properties, in vitro and animal in vivo data. ADME, PBPK
2022 Examining Physiologically Based Pharmacokinetic Model Assumptions for Cross-Tissue Similarity of Activity per Unit of Enzyme: The Case Example of Uridine 5'-Diphosphate Glucuronosyltransferase. PBPK, UGTs
2022 Exposure forecasting - ExpoCast - for data-poor chemicals in commerce and the environment. EPA
10  2022 In Vitro - in Vivo Extrapolation of Hepatic Clearance in Preclinical Species. ECCS, HEPs, LMs, SFs
11  2022 In vitro effects of opicapone on activity of human UDP-glucuronosyltransferases isoforms. COMT, DDIs, UGTs
12  2022 In Vitro to In Vivo Extrapolation Linked to Physiologically Based Pharmacokinetic Models for Assessing the Brain Drug Disposition. BBB, CNS, PBPK
13  2022 Potential herb-drug interaction risk of thymoquinone and phenytoin. CYP2C9
14  2022 The Environmental Pollutant Bromophenols Interfere With Sulfotransferase That Mediates Endocrine Hormones. BPs, Ki, PNP
15  2022 Towards best use and regulatory acceptance of generic physiologically based kinetic (PBK) models for in vitro-to-in vivo extrapolation (IVIVE) in chemical risk assessment. GMP, NAMs, PBK, QIVIVE
16  2022 Transport Turnover Rates for Human OCT2 and MATE1 Expressed in Chinese Hamster Ovary Cells. MATE1, OCT2, PBPK, TOR
17  2022 Validation of Methods for in Vitro-in Vivo Extrapolation Using Hepatic Clearance Measurements in Isolated Perfused Fish Livers. ---
18  2021 A comprehensive review on non-clinical methods to study transfer of medication into breast milk - A contribution from the ConcePTION project. PBPK
19  2021 A New Guidance for the Prediction of Hepatic Clearance in the Early Drug Discovery and Development from the in Vitro-to-in Vivo Extrapolation Method and an Approach for Exploring Whether an Albumin-Mediated Hepatic Uptake Phenomenon Could be Present Under in Vivo Conditions. ALB, CL
20  2021 An integrated exposure and pharmacokinetic modeling framework for assessing population-scale risks of phthalates and their substitutes. DEHA, DEHP, DEP, DINCH, DPHP
21  2021 Can In Vitro-In Vivo Extrapolation Be Successful? Recognizing the Incorrect Clearance Assumptions. ---
22  2021 Hepatic Scaling Factors for In Vitro-In Vivo Extrapolation of Metabolic Drug Clearance in Patients with Colorectal Cancer with Liver Metastasis. CPPGL, MPPGL, PBPK
23  2021 High-throughput PBTK models for in vitro to in vivo extrapolation. HTS, HTTK, PBTK, TK
24  2021 In vitro enantioselective inhibition of the main human CYP450 enzymes involved in drug metabolism by the chiral pesticide tebuconazole. CYP450, TEB
25  2021 Multi-organ-on-a-chip for pharmacokinetics and toxicokinetic study of drugs. PK, TK
26  2021 PBPK Modeling as a Tool for Predicting and Understanding Intestinal Metabolism of Uridine 5'-Diphospho-glucuronosyltransferase Substrates. DDIs, PBPK, UGTs
27  2021 Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Disposition of Imaging Biomarker Gadoxetate in Rats. DCE, MRI, MRP2, OATP1B1, PBPK, tDDI
28  2021 Physiologically-based pharmacokinetic modeling to evaluate in vitro-to-in vivo extrapolation for intestinal P-glycoprotein inhibition. DDIs, PBPK
29  2021 Prediction of Drug Clearance from Enzyme and Transporter Kinetics. PBPK
30  2021 Prediction of oral hepatotoxic dose of natural products derived from traditional Chinese medicines based on SVM classifier and PBPK modeling. BMC, DILI, NP-TCMs, PBPK, SVM
31  2021 Prediction of Oral Pharmacokinetics Using a Combination of In Silico Descriptors and In Vitro ADME Properties. AUCp,oral, ESFs
32  2021 Prediction of the dose range for adverse neurological effects of amiodarone in patients from an in vitro toxicity test by in vitro-in vivo extrapolation. AUC, ChAT, PBPK
33  2021 Quantitative In Vitro-to-In Vivo Extrapolation for Mixtures: A Case Study of Superfund Priority List Pesticides. ---
34  2021 Quaternary Ammonium Compounds: Bioaccumulation Potentials in Humans and Levels in Blood before and during the Covid-19 Pandemic. QACs
35  2020 Abundance and Associated Variations of Cytochrome P450 Drug-Metabolizing Enzymes in the Liver of East Asian Adults: A Meta-Analysis. PBPK
36  2020 Albumin-Mediated Uptake Improves Human Clearance Prediction for Hepatic Uptake Transporter Substrates Aiding a Mechanistic In Vitro-In Vivo Extrapolation (IVIVE) Strategy in Discovery Research. CL, CL, ESF, PSu,inf
37  2020 Chemical concentrations in cell culture compartments (C5) - free concentrations. fu, NAM
38  2020 Direct Comparison of Total Clearance Prediction: Computational Machine Learning Model versus Bottom-Up Approach Using In Vitro Assay. cfu,mic, ECCS, RBF, RF
39  2020 Effect of Human Plasma on Hepatic Uptake of Organic Anion-Transporting Polypeptide 1B Substrates: Studies Using Transfected Cells and Primary Human Hepatocytes. HEK, OATP
40  2020 Evaluating Lean Liver Volume as a Potential Scaler for In Vitro-In Vivo Extrapolation of Drug Clearance in Obesity Using the Model Drug Antipyrine. CL, LLV, LV
41  2020 Evaluation of the Disconnect between Hepatocyte and Microsome Intrinsic Clearance and In Vitro In Vivo Extrapolation Performance. HH, HLM
42  2020 Examining Uncertainty in In Vitro-In Vivo Extrapolation Applied in Fish Bioconcentration Models. BCFs
43  2020 In vitro-in vivo extrapolation of hepatic and gastrointestinal biotransformation rates of hydrophobic chemicals in rainbow trout. BaP, EHMC, OCT, PYR
44  2020 In vitro-invivo extrapolation of metabolic clearance using human liver microsomes: factors showing variability and their normalization. ---
45  2020 Inhibition of human UDP-glucuronosyltransferase enzyme by belinostat: Implications for drug-drug interactions. 4-MU, DDIs, HDAC, PTCL, TFP, UGTs
46  2020 Inhibition of UDP-glucuronosyltransferases (UGTs) by polycyclic aromatic hydrocarbons (PAHs) and hydroxy-PAHs (OH-PAHs). 4-MU, PAHs, UGTs
47  2020 Inhibition of UDP-glucuronosyltransferases by different furoquinoline alkaloids. 4-MU, HDIs, Ki, UGTs
48  2020 Investigating the Theoretical Basis for In Vitro-In Vivo Extrapolation (IVIVE) in Predicting Drug Metabolic Clearance and Proposing Future Experimental Pathways. ---
49  2020 Per- and polyfluoroalkyl substances exert strong inhibition towards human carboxylesterases. BMBT, CES, FD, Ki, PFDoA, PFOcDA, PFTA
50  2020 Predicting human tissue exposures to xenobiotics using a bottom-up physiologically-based biokinetic model CsA, DDI, PBK, PET, RSV
51  2020 The Segregated Intestinal Flow Model (SFM) for Drug Absorption and Drug Metabolism: Implications on Intestinal and Liver Metabolism and Drug-Drug Interactions. DDIs, SFM, SFM, TM
52  2020 Use of computational toxicology (CompTox) tools to predict in vivo toxicity for risk assessment. AED, BMD, CB, CompTox, CPF, HTTK-Pop, LOEL, MOA, PZ
53  2020 [Approach to drug efficacy and safety assessment based on functions of a human iPSC-derived neuronal network]. MEA
54  2019 Assessing Toxicokinetic Uncertainty and Variability in Risk Prioritization. HTTK
55  2019 Bottom-up physiologically-based biokinetic modelling as an alternative to animal testing. PBK, tmax
56  2019 Chemical concentrations in cell culture compartments (C5) - concentration definitions. NAM
57  2019 Considerations for Strategic Use of High-Throughput Transcriptomics Chemical Screening Data in Regulatory Decisions. BPACs, HTS, HTTr, NAMs
58  2019 Dissecting the Contribution of OATP1B1 to Hepatic Uptake of Statins Using the OATP1B1 Selective Inhibitor Estropipate. DDI, EPP, fT, OATP
59  2019 Importance of in vitro conditions for modeling the in vivo dose in humans by in vitro-in vivo extrapolation (IVIVE). PBPK, PHH
60  2019 Incorporating new approach methodologies in toxicity testing and exposure assessment for tiered risk assessment using the RISK21 approach: Case studies on food contact chemicals. HTS
61  2019 Inhibition of UDP-glucuronosyltransferases (UGTs) by bromophenols (BPs). 4-MU, BPs, DMEs, UGTs
62  2019 Ketamine analogues: Comparative toxicokinetic in vitro-in vivo extrapolation and quantification of 2-fluorodeschloroketamine in forensic blood and hair samples. 2F-DCK, fu, NPS
63  2019 Species differences in metabolism of a new antiepileptic drug candidate, DSP-0565 [2-(2'-fluoro[1,1'-biphenyl]-2-yl)acetamide]. ---
64  2019 The potential protein-mediated hepatic uptake: discussion on the molecular interactions between albumin and the hepatocyte cell surface and their implications for the in vitro-to-in vivo extrapolations of hepatic clearance of drugs. ALB
65  2019 The Regional-Specific Relative and Absolute Expression of Gut Transporters in Adult Caucasians: A Meta-Analysis. MRP, OCTN1, PBPK, PepT1
66  2019 Three-dimensional tissue engineering-based Dentin/Pulp tissue analogue as advanced biocompatibility evaluation tool of dental restorative materials. ---
67  2019 Using the concordance of in vitro and in vivo data to evaluate extrapolation assumptions. fup, PBTK
68  2019 Utility of Chimeric Mice with Humanized Liver for Predicting Human Pharmacokinetics in Drug Discovery: Comparison with in Vitro-in Vivo Extrapolation and Allometric Scaling. CL, PK, Vd
69  2018 Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxaban. DDI, PBPK
70  2018 Concentration dependence of in vitro biotransformation rates of hydrophobic organic sunscreen agents in rainbow trout S9 fractions: Implications for bioaccumulation assessment. 4-MBC, BCFs, EHMC, NADPH, UVFs
71  2018 Development of a human physiologically based pharmacokinetic (PBPK) model for phthalate (DEHP) and its metabolites: A bottom up modeling approach. EDCs, PBPK, QSAR, WHO
72  2018 Evaluating In Vitro-In Vivo Extrapolation of Toxicokinetics. HTTK, TK, Vd
73  2018 Evaluation and Optimization of Pharmacokinetic Models for in Vitro to in Vivo Extrapolation of Estrogenic Activity for Environmental Chemicals. EF, ER, LELs, PK, U.S. EPA
74  2018 Extrapolation of the Hepatic Clearance of Drugs in the Absence of Albumin InVitro to That in the Presence of Albumin InVivo: Comparative Assessement of 2 Extrapolation Models Based on the Albumin-Mediated Hepatic Uptake Theory and Limitations and Mechanistic Insights. ALB, CL, CL, FDM
75  2018 Improving Prediction of Metabolic Clearance Using Quantitative Extrapolation of Results Obtained From Human Hepatic Micropatterned Cocultures Model and by Considering the Impact of Albumin Binding. ALB, CL
76  2018 In Vitro- in Vivo Extrapolation of Hepatic Metabolism for Different Scenarios - a Toolbox. ---
77  2018 In vitro-to-in vivo extrapolation (IVIVE) by PBTK modeling for animal-free risk assessment approaches of potential endocrine-disrupting compounds. PBTK, YAS, YES
78  2018 Performance evaluation of the GastroPlusTM software tool for prediction of the toxicokinetic parameters of chemicals. AUC, fup, PBPK
79  2018 Strategies to improve the prediction accuracy of hepatic intrinsic clearance of three antidiabetic drugs: Application of the extended clearance concept and consideration of the effect of albumin on CYP2C metabolism and OATP1B-mediated hepatic uptake. OATP
80  2018 The Importance of Incorporating OCT2 Plasma Membrane Expression and Membrane Potential in IVIVE of Metformin Renal Secretory Clearance. ---
81  2018 Towards Further Verification of Physiologically-Based Kidney Models: Predictability of the Effects of Urine-Flow and Urine-pH on Renal Clearance. CLR
82  2017 A physiologically based pharmacokinetic modelling approach to predict buprenorphine pharmacokinetics following intravenous and sublingual administration. BUP, PBPK, SL
83  2017 An Intuitive Approach for Predicting Potential Human Health Risk with the Tox21 10k Library. fup, HTS, TK
84  2017 Comparison of the Predictability of Human Hepatic Clearance for Organic Anion Transporting Polypeptide Substrate Drugs Between Different InVitro-InVivo Extrapolation Approaches. OATP
85  2017 Everolimus-inhibited multiple isoforms of UDP-glucuronosyltransferases (UGTs). Ki, mTOR, UGTs
86  2017 Inhibitory effects of tanshinones towards the catalytic activity of UDP-glucuronosyltransferases (UGTs). 4-MU, AUC, HPLC, Ki, UGTs
87  2017 Novel Method to Predict In Vivo Liver-to-Plasma Kpuu for OATP Substrates Using Suspension Hepatocytes. ---
88  2017 Strategy for CYP3A Induction Risk Assessment from Preclinical Signal to Human: a Case Example of a Late-Stage Discovery Compound. 4betaHC, DDI, PBPK
89  2017 The Constraints, Construction, and Verification of a Strain-Specific Physiologically Based Pharmacokinetic Rat Model. i.v, PBPK
90  2016 Advancing In Vitro-In Vivo Extrapolations of Mechanism-Specific Toxicity Data Through Toxicokinetic Modeling. ECHA
91  2016 Biotransformation of the fungal neurotoxin Thomitrem A by primary rat hepatocytes. ---
92  2016 Inhibition of human catechol-O-methyltransferase-mediated dopamine O-methylation by daphnetin and its Phase II metabolites. COMT, HLC
93  2016 InVitro-InVivo Extrapolation of Intestinal Availability for Carboxylesterase Substrates Using Portal Vein-Cannulated Monkey. CES, PBPK
94  2016 Key to Opening Kidney for In Vitro-In Vivo Extrapolation Entrance in Health and Disease: Part I: In Vitro Systems and Physiological Data. PBPK
95  2016 Key to Opening Kidney for In Vitro-In Vivo Extrapolation Entrance in Health and Disease: Part II: Mechanistic Models and In Vitro-In Vivo Extrapolation. ---
96  2016 New IVIVE method for the prediction of total human clearance and relative elimination pathway contributions from in vitro hepatocyte and microsome data. ECCCS, ECM
97  2016 Novel minimal physiologically-based model for the prediction of passive tubular reabsorption and renal excretion clearance. CLR
98  2016 Pathway Based Toxicology and Fit-for-Purpose Assays. ---
99  2016 Quantitative prediction of human pharmacokinetics and pharmacodynamics of imigliptin, a novel DPP-4 inhibitor, using allometric scaling, IVIVE and PK/PD modeling methods. AS, FIH, PK/PD
100  2016 Scaling factors for the in vitro-in vivo extrapolation (IV-IVE) of renal drug and xenobiotic glucuronidation clearance. CLUGT, Def, HLM, MOR, MPPGK, PRO